CAR-T细胞疗法免疫效应细胞嵌合抗原受体T细胞疗法被美国临床肿瘤学会评为2017年最大的研究突破,现正迅速成为治疗血液学恶性肿瘤最有前途的一项新疗法,但同时也带来了新的挑战——细胞因子释放综合征和神经毒性等,有时甚至会引起患者的死亡.在不同的多中心试验报告中,以上毒性事件的发生率和严重程度也不尽相同,究其原因是对毒性的评估
DEFINITION OF FEVER, HYPOTENSION, AND HYPOXIA AS RELATED TO CRS GRADING DEFINITION OF CRS RESOLUTION Symptoms of ICANS DEFINITION OF ICANS SYMPTOMS AND SIGNS EXCLUDED FROM THE DEFINITION OF ICANS CONSENSUS ON ICANS GRADING FOR ADULTS CONSENSUS ON ICANS GRADING FOR CHILDREN DATA COLLECTION AND REPORTING...
Multiple publications had demonstrated that CAR-T effectiveness is maintained in the real-world setting, and that rates and severities of toxicities, specifically CRS and ICANS, have decreased as consensus recommendations and newer data on preemptive/prophylactic management strategies have been published ...
嵌合抗原受体 T 细胞疗法 CRS/ICANS 反应的 ASTCT 共识解读doi:10.19746/j.cnki.issn1009-2137.2021.06.051傅琤琤王如菊吴德沛Journal of Experimental Hematology / Zhongguo Shiyan Xueyexue Zazhi
CRS and ICANS were retrospectively graded according to the new ASTCT consensus grading system, for comparison with other available systems: Lee, Penn, Memorial Sloan Kettering Cancer Center, CARTOX and CTCAEv5.0 for CRS; CTCAEv4.03 and CARTOX for ICANS. We then used ASTCT grades to predict ...